Skip to main content
DOC logo

DOC · Healthpeak Properties, Inc.

Track DOC — free
$19.69 -0.30 (-1.48%)
Market Cap
$13.78B
Shares
689.54M
Volume · Nov 16 1.91M Avg daily vol (3M) 5.49M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$19.98 Open$20.09 Day$19.83–20.17 52W close$15.78–22.82 Avg vol 30d6.2M Short int22.9M · 3.3% of shares · 4.0d Short vol57% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 2, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Janus Living IPO gives Healthpeak 69.2% voting and economic rights

Healthpeak Properties, Inc. received 138,816,246 Janus Living Class A-1 shares and 75,917,780 Janus Living OP units through IPO formation transactions, providing 69.2% voting and economic rights as of September 30, 2026.

Revenue $820.89M ▲ 16.3% Net income $17.26M Diluted EPS $0.02
Read from the MD&A section
3 source passages
Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States (“U.S.”). As a result of these transactions, we received 138,816,246 shares of Janus Living’s Class A-1 common stock and 75,917,780 common units in the Janus Living OP, LLC (“Janus Living OP”), Janus Living’s operating subsidiary. As of September 30, 2026, our ownership of the Janus Living Class A-1 and Class A-2 common shares, together with our ownership of common units of Janus Living OP, provides us with voting and economic rights of 69.2% of Janus Living. Open the document at this passage
Nov 3
Earnings call
FFO guidance raised for third time in 2026

Healthpeak raised 2026 adjusted FFO guidance for the third consecutive quarter, lifting the midpoint by two cents to a range of $1.76 to $1.78 per share, citing stronger portfolio leasing and operating performance.

3 source passages
Health Peak Properties, Inc. third quarter, 2026 conference call. We raised our FFO's adjusted guidance for the third consecutive quarter by two cents at the midpoint to a range of $1.76 to $1.78 per share. The update to our guidance reflects stronger leasing across the portfolio, the delayed timing of our remaining dispositions, and highlights the strength of our operating performance year to date Open the document at this passage
Nov 2
Current report 8-K
Financial results, Regulation FD disclosure

Healthpeak reported third-quarter net income of $0.02 per share and FFO as Adjusted of $0.44 per share, increased full-year FFO as Adjusted guidance to $1.76 - $1.78, and reported Janus Living revenue of $268 million, up 78%.

Read from the first part of this long document
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $771.58M ▲ 11.1% Net income $52.82M ▲ 66.8% Diluted EPS $0.08 ▲ 60.0%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.06B
Trailing 12 months
Net income (TTM)
$377.68M
Trailing 12 months
Revenue growth YoY
+16.3%
Year over year
Operating margin
—
Trailing 12 months
P / FFO
11.0×
Company-stated · FY2025 · reciprocal yield 9.1%
P / AFFO
11.8×
Company-stated · FY2025 · reciprocal yield 8.5%
P / E (TTM)
37.0
Trailing earnings · reciprocal yield 2.7%
Net cash
−$8.87B
Latest balance sheet
Dividend yield
6.1%
Trailing 12 months
Shares change YoY
-0.8%
Year over year · fewer shares
Price change (1Y)
+14.1%
Trailing year
Short interest
3.3%
Latest settlement · 4.0 days to cover
View all 129 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Healthpeak raised FFO as Adjusted guidance, while Janus Living grew revenue and Adjusted EBITDAre, lab occupancy improved, and outpatient leasing remained strong. Investors still face lower diluted earnings guidance, negative Lab same-store performance and guidance, refinancing pressure, and an initial occupancy reset from the life science acquisitions.

Bullish
  • + Healthpeak raised its 2026 FFO as Adjusted guidance for the third consecutive quarter.
  • + Janus Living delivered strong year-over-year revenue and Adjusted EBITDAre growth.
  • + Lab occupancy and leasing momentum improved, with occupancy up 270 basis points since year-end 2025.
  • + Outpatient Medical leasing remained strong, with year-to-date lease executions of 3.2 million square feet.
  • + Healthpeak acquired or is under contract to acquire four life science buildings totaling approximately 510,000 square feet across three campuses for approximately $233 million.
  • + Healthpeak had approximately $3.8 billion of liquidity as of October 30, 2026.
Bearish
  • − Healthpeak reduced its 2026 diluted earnings-per-share guidance by $0.10 at the midpoint.
  • − Third-quarter diluted FFO as Adjusted per share was $0.44 versus $0.46 in the prior-year quarter.
  • − Lab same-store adjusted NOI declined 0.7% year over year.
  • − Healthpeak's full-year Lab same-store guidance remains negative at down 3% to down 6%.
  • − Maturing debt carries an approximately 3% borrowing cost that is below current market rates.
  • − The life science acquisitions will initially reduce reported occupancy because the acquired campuses are only 41% occupied.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +4%
above
Price vs 50-day avg +2%
above
RSI (14) 54
neutral
MACD trend Positive
52-week position 60%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +5%
trailing
6-month return 0%
trailing
YTD return +24%
this year
Relative strength −1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow Accumulating
701 of 773 funds reported for Sep 30 · net +3.7M sh shares · +78 new
Insider flow Distributing
Net -$127.1K over 90 days · 100% sells
Short interest Rising
3.31% of shares out · ▲ +5.2% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
773 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Weak
Revenue growth +5%
Y/Y
EPS growth −72%
Y/Y
Valuation P/E 37
in line
Buyback $500.0M
remaining
Balance sheet $9.4B
net debt
Quant / Vol
risk profile
Moderate
Volatility 29%
annualized · 1-yr
Max drawdown −19%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 3, 2026
at stabilization
Yield at stabilization 9% – 10%
this year
FFOs adjusted Non-GAAP $1.76 – $1.78
Outpatient medical 2.5% – 3%
Total same store 0.5% – 2%
Senior housing 16% – 19%
Previous outlook earlier release · from the 8-K filed Nov 2, 2026

Still-open targets the latest release did not restate under the same label.

Diluted FFO as Adjusted per share · Full Year 2026 $1.76 – $1.78
Total Same-Store Cash (Adjusted) NOI · Full Year 2026 0.5% – 2%
Diluted earnings per common share · 2026 $0.39 – $0.41
Diluted FFO as Adjusted per common share · 2026 $1.76 – $1.78
Real estate related depreciation and amortization · 2026 Guidance Ranges $1.70
Healthpeak's share of real estate related depreciation and amort · 2026 Guidance Ranges $0.04
Noncontrolling interests' share of real estate related depreciat · 2026 Guidance Ranges $-0.11
Loss (gain) on sales of depreciable real estate, net · 2026 Guidance Ranges $-0.09
Loss (gain) upon change of control, net · 2026 Guidance Ranges $-0.20
Taxes associated with real estate dispositions · 2026 Guidance Ranges $-0.01
Transaction, merger, and restructuring-related costs · 2026 Guidance Ranges $0.06
Other impairments (recoveries) and other losses (gains), net · 2026 Guidance Ranges $-0.01
Recognition (reversal) of valuation allowance on deferred tax as · 2026 Guidance Ranges $0.00
Casualty-related charges (recoveries), net · 2026 Guidance Ranges $-0.01
Guided vs delivered · last 1 settled
Diluted earnings per common share full year 2025
guided $0.00 – $0.06
$0.10 Beat +233.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+4% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
54 Neutral
MACD trend
Positive Bullish
52-week position
60% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow Accumulating
701 of 773 funds reported for Sep 30 · net +3.7M sh shares · +78 new
Insider flow Distributing
Net -$127.1K over 90 days · 100% sells
Short interest Rising
3.31% of shares out · ▲ +5.2% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
773 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16 Now $20 · 60% Range high $23
vs 200-day avg +4% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjustments to NOI(1) non-GAAP -62.69M For the nine months ended September 30, 2026 —
Annualized Adjusted EBITDAre(1) non-GAAP 1.89B Three Months EndedSeptember 30, 2026 —
Current Quarter Total Property Count 726 As of September 30, 2026 —
EBITDAre 432.37M Three Months EndedSeptember 30, 2026 —
Financial Leverage 34.2% September 30, 2026 —
Fixed Charge Coverage Adjusted EBITDAre(2) non-GAAP 462.77M Three Months EndedSeptember 30, 2026 —
Lab new and renewal lease executions 480,000 THIRD QUARTER 2026 —
Lab total occupancy 270 since year-end 2025 —
Nine-Month SS Property Count 593 As of September 30, 2026 —
NOI 1.23B For the nine months ended September 30, 2026 —
Non-SS Adjusted NOI non-GAAP -221.4M For the nine months ended September 30, 2026 —
Noncontrolling interests' share of consolidated joint venture NOI non-GAAP 69.51M nine months ended September 30, 2026 —
Outpatient Medical lease executions 3.2M year-to-date —
Outpatient Medical new and renewal lease executions 846,000 THIRD QUARTER 2026 —
Portfolio Adjusted NOI non-GAAP 1.17B For the nine months ended September 30, 2026 —
Same-store Adjusted NOI non-GAAP 25.9% third quarter —
Secured Debt Ratio 1.2% September 30, 2026 —
SS Adjusted NOI non-GAAP 947.25M For the nine months ended September 30, 2026 —
Three-Month SS Property Count 600 As of September 30, 2026 —
Total Adjusted Net Operating Income non-GAAP $76M third quarter —
Adjusted NOI % change non-GAAP 2.5% Three Months Ended June 30, 2026 filing —
Average annual base rent per occupied square foot $67 Three Months Ended June 30, 2026 filing —
Average annual base rent per occupied square foot (Outpatient Medical Same-Store) $29 Three Months Ended June 30, 2026 filing —
Average annual rent per occupied square foot $92 Three Months Ended June 30, 2026 filing —
Average annual rent per occupied square foot (Outpatient Medical Same-Store) $39 Three Months Ended June 30, 2026 filing —
Average occupancy 90.5% Three Months Ended June 30, 2026 filing —
Average occupancy (Outpatient Medical Same-Store) 91.9% Three Months Ended June 30, 2026 filing —
Average occupancy (Senior Housing Same-Store) 88.6% Three Months Ended June 30, 2026 filing —
Average occupancy (Senior Housing Total Portfolio) 85.5% Three Months Ended June 30, 2026 filing —
Average occupancy (Total Portfolio) 87.7% Three Months Ended June 30, 2026 filing —
Average occupied square feet 7.07M Three Months Ended June 30, 2026 filing —
Average occupied square feet (Outpatient Medical Same-Store) 31.38M Three Months Ended June 30, 2026 filing —
Average occupied square feet (Total Portfolio) 9.6M Three Months Ended June 30, 2026 filing —
Average occupied units (Senior Housing Same-Store) 6,260 Three Months Ended June 30, 2026 filing —
Average occupied units (Senior Housing Total Portfolio) 9,004 Three Months Ended June 30, 2026 filing —
End of period occupancy 90.3% Three Months Ended June 30, 2026 filing —
End of period occupancy (Outpatient Medical Same-Store) 91.9% Three Months Ended June 30, 2026 filing —
End of period occupancy (Outpatient Medical Total Portfolio) 91.5% Three Months Ended June 30, 2026 filing —
End of period occupancy (Total Portfolio) 87.5% Three Months Ended June 30, 2026 filing —
Property count 101 Three Months Ended June 30, 2026 filing —
Property count (Outpatient Medical Same-Store) 484 Three Months Ended June 30, 2026 filing —
Property count (Senior Housing Same-Store) 15 Three Months Ended June 30, 2026 filing —
Property count (Senior Housing Total Portfolio) 41 Three Months Ended June 30, 2026 filing —
Property count (Total Portfolio) 141 Three Months Ended June 30, 2026 filing —
RevPOR per month (Senior Housing Same-Store) $8,589 Three Months Ended June 30, 2026 filing —
RevPOR per month (Senior Housing Total Portfolio) $7,484 Three Months Ended June 30, 2026 filing —
Adjusted EBITDAre non-GAAP $455.47M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
EBITDAre 440.68M (non-GAAP)
+9.17M Transaction, merger, and restructuring-related costs
-1.48M Other impairments (recoveries) and other losses (gains)
-5.51M Casualty-related charges (recoveries)
+12.87M Non-refundable entrance fee sales in excess of (less than) the related GAAP amortization
+4.35M Stock-based compensation amortization expense
-4.61M Impact of transactions closed during the period
= Adjusted EBITDAre 455.47M
Adjusted EBITDAre (Janus Living) non-GAAP $79M the prior year quarter comparison, second quarter 2026 —
Average occupied units/month 8,672 Six Months Ended June 30, 2026 —
Diluted FFO as Adjusted applicable to common shares non-GAAP 325.42M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
FFO as Adjusted applicable to common shares 321.03M (non-GAAP)
+4.38M Distributions on dilutive convertible units and other
= Diluted FFO as Adjusted applicable to common shares 325.42M
Diluted Nareit FFO applicable to common shares non-GAAP $323.35M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
Nareit FFO applicable to common shares 318.97M (non-GAAP)
+4.38M Distributions on dilutive convertible units and other
= Diluted Nareit FFO applicable to common shares 323.35M
Enterprise Debt $10.24B June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Consolidated Debt 10.03B
+212.25M Share of unconsolidated JV mortgage debt
= Enterprise Debt 10.24B
FFO as Adjusted applicable to common shares non-GAAP 321.03M three months ended June 30, 2026 —
Healthpeak equity ownership of Janus Living 73.6% as of June 30, 2026 —
Lab new lease executions 222,000 the second quarter —
Lab renewal lease executions 159,000 the second quarter —
Net Debt non-GAAP 8.51B June 30, 2026 —
GAAP → non-GAAP reconciliation
Enterprise Debt 10.24B (the result of another reconciliation in this filing)
-1.63B Cash and cash equivalents
-9.29M Share of unconsolidated JV cash and cash equivalents
-91.86M Restricted cash
-1.65M Share of unconsolidated JV restricted cash
= Net Debt 8.51B
Outpatient Medical new lease executions 327,000 the second quarter —
Outpatient Medical renewal lease executions 916,000 the second quarter —
Portfolio Cash Real Estate Revenues non-GAAP 689.86M Three Months Ended June 30, 2026 —
Same-store Adjusted NOI increase (Janus Living) non-GAAP 19.2% second quarter 2026 —
Six-Month SS Property Count 596 Six Months Ended June 30, 2026 —
SS Cash Real Estate Revenues non-GAAP 564.28M Three Months Ended June 30, 2026 —
Total Adjusted Net Operating Income (Janus Living) non-GAAP $58M second quarter 2026 —
Total occupancy (Lab) 78.5% the second quarter —
Total occupancy (Outpatient Medical) 90.7% the second quarter —
Year-Over-Year Same-Store Adjusted NOI Growth (Outpatient Medical) non-GAAP 2.5% Three Month —
Year-Over-Year Same-Store Adjusted NOI Growth (Senior Housing) non-GAAP 19.2% Three Month —
Year-Over-Year Same-Store Adjusted NOI Growth (Total) non-GAAP 1.8% Three Month —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

REIT - Healthcare Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DOC
Healthpeak Properties, Inc.
this stock
$13.78B +24.3% +4.5% 37.0 3.3%
WELL
Welltower Inc.
$179.34B +31.7% +35.6% 106.3 2.4%
VTR
Ventas, Inc.
$47.02B +14.9% +18.5% 167.8 2.8%
OHI
Omega Healthcare Investors Inc
$14.32B +6.1% +13.2% 18.9 4.8%
AHR
American Healthcare REIT, Inc.
$13.41B +22.8% +9.1% 115.6 14.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
805
% held
96.3%
Reported
701 of 773
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
601
View
Short & Settlement
Short Interest Rising
Shares short
22.9M
Days to cover
4.0d
Change
+1.1M sh
View
Short Volume
Short vol %
57%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
2.4K
Value
$43.8K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
46.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$127.1K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$2.8B
Net income (FY)
$71.3M
EPS diluted
$0.10
View
Buybacks
Authorized
$500.0M
Remaining
$500.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
15

Healthpeak Properties, Inc. received 138,816,246 Janus Living Class A-1 shares and 75,917,780 Janus Living OP units through IPO formation transactions, providing 69.2% voting and economic rights as of September 30, 2026.

View
Proposed Sales
Value
$127.0K
Shares
6.1K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
Healthpeak Properties Reports Thi…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
DOC -1.4% +5.3% -0.3% +5.0% +24.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -4.0% +6.4% -0.8% +5.2% +13.6%

Capital returns

Latest dividend
$0.102 / share · ex Nov 13, 2026
Declared · upcoming
$0.1017 / share · ex Dec 18, 2026
Cut 66.6%
Paid (TTM)
$1.224 / share · 12 payouts
Dividend yield (TTM, derived)
6.13%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$500.00M
Spent (derived)
$0
Remaining
$500.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 765880 CUSIP 42250P103 13F (30d) 598 filings 558 filers Visit website Investor relations